TY - JOUR
T1 - Liver disease associated with anti-liver-kidney microsome antibody in children
AU - Maggiore, Giuseppe
AU - Bernard, Olivier
AU - Homberg, Jean Claude
AU - Hadchouel, Michelle
AU - Alvarez, Fernando
AU - Hadchouel, Paul
AU - Odièvre, Michel
AU - Alagille, Daniel
N1 - Funding Information:
Supported by a grant from Foundazione Anna Villa Rusconi, Varese, Italy (G.M.). Submitted for publication ApriI 9, 1985; accepted Sept. 10, 1985. Reprint requests: G. Maggiore, M.D., Clinica Pediatrica dell'UniversitY, Policlinico San Matteo, Piazzale Golgi, 27100 Pavia, ltary.
PY - 1986/1/1
Y1 - 1986/1/1
N2 - In the past 10 years we have examined 20 children with inflammatory liver disease associated with high serum titers of anti-liver-kidney microsome antibody (anti-LKM). The first hepatic symptoms were progressive fatigue and jaundice, the fortuitous finding of hepatomegaly or splenomegaly with raised transaminase activity, or an acute hepatitis-like illness. At the time of diagnosis, hepatomegaly was present in 18 children, splenomegaly in 16, jaundice in nine, and ascites in two. Serum alanine transferase activities were elevated in all but two, who had already received steroids. Serum total gammaglobulin values were >2.0 gm/dl in 16 children, prothrombin activity ≤60% in six, and serum titer of anti-LKM between 1:100 and 1:100,000. All children but one had cirrhosis, and histologic signs of aggressivity were present in 14. In 11 children one or more extrahepatic diseases were present, including type 1 diabetes, vitiligo, glomerulonephritis, autoimmune hemolytic anemia, hypoglycemia with hyperinsulinism, autoimmune thyroiditis, chronic mucocutaneous candidiasis with hypoparathyroldism, and multiple cutaneous and visceral telanglectasias. Treatment with prednisone and azathioprine improved the liver condition in 16 of the 18 patients given treatment. In eight of them discontinuation of treatment resulted in rapid relapse; 14 are still receiving treatment and have stable hepatic function with follow-up from 8 months to 6 1/2 years. Only two are free of treatment. Four children died, two in spite of immunosuppressive therapy, one during a relapse, and one of extrahepatic disease. These results indicate that this autoimmune inflammatory liver disease (1) may have onset early in life, with several clinical patterns; (2) is frequently associated with certain types of extrahepatic manifestations of autoimmune origin; and (3) is a potentially fatal disease for which immunosuppressive treatment must be started early.
AB - In the past 10 years we have examined 20 children with inflammatory liver disease associated with high serum titers of anti-liver-kidney microsome antibody (anti-LKM). The first hepatic symptoms were progressive fatigue and jaundice, the fortuitous finding of hepatomegaly or splenomegaly with raised transaminase activity, or an acute hepatitis-like illness. At the time of diagnosis, hepatomegaly was present in 18 children, splenomegaly in 16, jaundice in nine, and ascites in two. Serum alanine transferase activities were elevated in all but two, who had already received steroids. Serum total gammaglobulin values were >2.0 gm/dl in 16 children, prothrombin activity ≤60% in six, and serum titer of anti-LKM between 1:100 and 1:100,000. All children but one had cirrhosis, and histologic signs of aggressivity were present in 14. In 11 children one or more extrahepatic diseases were present, including type 1 diabetes, vitiligo, glomerulonephritis, autoimmune hemolytic anemia, hypoglycemia with hyperinsulinism, autoimmune thyroiditis, chronic mucocutaneous candidiasis with hypoparathyroldism, and multiple cutaneous and visceral telanglectasias. Treatment with prednisone and azathioprine improved the liver condition in 16 of the 18 patients given treatment. In eight of them discontinuation of treatment resulted in rapid relapse; 14 are still receiving treatment and have stable hepatic function with follow-up from 8 months to 6 1/2 years. Only two are free of treatment. Four children died, two in spite of immunosuppressive therapy, one during a relapse, and one of extrahepatic disease. These results indicate that this autoimmune inflammatory liver disease (1) may have onset early in life, with several clinical patterns; (2) is frequently associated with certain types of extrahepatic manifestations of autoimmune origin; and (3) is a potentially fatal disease for which immunosuppressive treatment must be started early.
UR - http://www.scopus.com/inward/record.url?scp=0022620605&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(86)80880-0
DO - 10.1016/S0022-3476(86)80880-0
M3 - Article
C2 - 3950819
AN - SCOPUS:0022620605
SN - 0022-3476
VL - 108
SP - 399
EP - 404
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 3
ER -